Organon &

Organon & Financial Leverage

The Financial Leverage (Equity Multiplier) of Organon & (OGN) as of Oct 30, 2026 is 17.11. In the previous year, Financial Leverage (Equity Multiplier) was 27.76 — a change of -38.36% (lower).

Financial Leverage

17.11

YoY

-38.36%

Last updated:

Financial Leverage (Equity Multiplier) of Organon & is 2025 17.11 . Financial Leverage (Equity Multiplier) of Organon & was 2024 27.76 . It decreases by -38.36% lower compared to the previous year.

The Organon & Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.65 USD
Jan 1, 2019
1.50 USD
Jan 1, 2020
1.84 USD
Jan 1, 2021
-7.08 USD
Jan 1, 2022
-12.28 USD
Jan 1, 2023
-172.26 USD
Jan 1, 2024
27.76 USD
Jan 1, 2025
17.11 USD
The Organon & Financial Leverage history
YEARFinancial LeverageYoY
17.11-38.36%
27.76-116.11%
-172.26+1,302.59%
-12.28+73.40%
-7.08-484.38%
1.84+22.90%
1.50-9.30%
1.65—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers. Organon & is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Organon & stock

Financial Leverage (Equity Multiplier) of Organon & is 17.11 in 2025.

Financial Leverage (Equity Multiplier) of Organon & changed from 27.76 to 17.11, representing a -38.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Organon & since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Organon & with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Organon &

All Key Metrics — Organon &